Stem cell exosome therapy for frontotemporal dementia
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This trial tests a new treatment using tiny particles from stem cells (exosomes) given through an IV. It aims to slow down or improve symptoms of frontotemporal dementia, a type of dementia that affects behavior and language.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with frontotemporal dementia (FTD), including the behavioral or language variants.
- You are between 30 and 80 years old.
- You have a study partner (like a family member or friend) who can spend at least 3 hours a day with you and help manage your care.
- Your dementia is at an early to moderate stage (score of 0-2 on a specific dementia rating scale and a score above 10 on a memory test).
- You have been on stable medications for memory or behavior for at least 30 days.
- You do not have other serious medical conditions, a history of stroke, or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if vortioxetine, an antidepressant, can improve mood symptoms (like depression or anxiety) and thinking abilities in people with frontotemporal dementia (FTD). It also includes healthy volunteers for comparison.
This trial tests a new gene therapy called AVB-101 for people with a specific genetic cause of frontotemporal dementia (FTD). The therapy is given as a one-time injection into the brain to potentially slow or stop the disease.
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
This study tests a new treatment using tiny particles from stem cells (called exosomes) given as a nasal spray. It aims to see if it can help people with early-onset Alzheimer's disease, which starts before age 65.
This study tests a new treatment using exosomes (tiny particles from stem cells) given through a vein to people who recently had an ischemic stroke. It aims to see if this treatment is safe and helps improve recovery.
This trial tests an experimental treatment made from stem cells (exosomes) given within a week of a stroke, to see if it can help the brain recover. It is designed for people with moderate stroke symptoms who were otherwise healthy before the stroke.
Hear when a new Frontotemporal Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.